Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Santaolalla, Aida"'
Autor:
Beckmann KR; Cancer Epidemiology and Population Health Research, University of South Australia, Adelaide, South Australia, Australia.; Translational Oncology and Urology Research, Kings College London, London, UK., Bangma CH; Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Helleman J; Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Bjartell A; Department of Translational Medicine, Skane University Hospital, Malmo, Sweden., Carroll PR; Department of Urology, University of California San Francisco, San Francisco, California, USA., Morgan T; Michigan Urological Surgery Improvement Collaborative, University of Michigan, Ann Arbor, Michigan, USA., Nieboer D; Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Santaolalla A; Translational Oncology and Urology Research, Kings College London, London, UK., Trock BJ; The James Buchanan Brady Urological Institute, John Hopkins University, Baltimore, Maryland, USA., Valdagni R; Radiation Oncology and Prostate Cancer Program, Istituto Nazionale Dei Tumori, Milano, Italy., Roobol MJ; Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Publikováno v:
The Prostate [Prostate] 2022 May; Vol. 82 (7), pp. 876-879. Date of Electronic Publication: 2022 Mar 07.
Autor:
Singh S; School of Medical Education, Faculty of Life Sciences and Medicine, King's College London, London, UK.; The Urology Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK., Sandhu P; School of Medical Education, Faculty of Life Sciences and Medicine, King's College London, London, UK.; The Urology Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK., Beckmann K; Translational Oncology and Urology Research, Faculty of Life Sciences and Medicine, King's College London, London, UK.; University of South Australia Cancer Research Institute, University of South Australia, Adelaide, SA, Australia., Santaolalla A; Translational Oncology and Urology Research, Faculty of Life Sciences and Medicine, King's College London, London, UK., Dewan K; School of Medical Education, Faculty of Life Sciences and Medicine, King's College London, London, UK., Clovis S; The Urology Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK., Rusere J; The Urology Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK., Zisengwe G; The Urology Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK., Challacombe B; The Urology Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK., Brown C; The Urology Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK., Cathcart P; The Urology Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK., Popert R; The Urology Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK., Dasgupta P; The Urology Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK.; School of Immunology and Microbial Sciences, Kings College London, London, UK., Van Hemelrijck M; Translational Oncology and Urology Research, Faculty of Life Sciences and Medicine, King's College London, London, UK., Elhage O; The Urology Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK.; School of Immunology and Microbial Sciences, Kings College London, London, UK.
Publikováno v:
BJU international [BJU Int] 2021 Jul; Vol. 128 (1), pp. 72-78. Date of Electronic Publication: 2020 Nov 15.
Autor:
Kum F; Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK.; Faculty of Life Sciences & Medicine, King's College London, London, UK., Beckmann K; Cancer Research Institute, University of South Australia, Adelaide, SA, Australia. kerri.beckmann@unisa.edu.au.; Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. kerri.beckmann@unisa.edu.au., Aya H; Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK.; Faculty of Life Sciences & Medicine, King's College London, London, UK., Singh S; Faculty of Life Sciences & Medicine, King's College London, London, UK., Sandhu P; Faculty of Life Sciences & Medicine, King's College London, London, UK., Sra S; Faculty of Life Sciences & Medicine, King's College London, London, UK., Rusere J; Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Zisengwe G; Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Santaolalla A; Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK., Cathcart P; Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Challacombe B; Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK.; Faculty of Life Sciences & Medicine, King's College London, London, UK., Brown C; Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Popert R; Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Dasgupta P; Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK.; School of Immunology and Microbial Sciences, Kings College London, London, UK., Van Hemelrijck M; Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK., Elhage O; Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK.; School of Immunology and Microbial Sciences, Kings College London, London, UK.
Publikováno v:
Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2021 Jun; Vol. 24 (2), pp. 549-557. Date of Electronic Publication: 2021 Feb 08.
Autor:
Shah S; King's College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology & Urology Research (TOUR), London, UK., Beckmann K; King's College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology & Urology Research (TOUR), London, UK.; Cancer Research Institute, University of South Australia, Adelaide, Australia., Van Hemelrijck M; King's College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology & Urology Research (TOUR), London, UK., Challacombe B; King's College London, London, UK & Guy's and St Thomas' NHS Foundation Trust, London, UK., Popert R; King's College London, London, UK & Guy's and St Thomas' NHS Foundation Trust, London, UK., Dasgupta P; King's College London, London, UK & Guy's and St Thomas' NHS Foundation Trust, London, UK., Rusere J; King's College London, London, UK & Guy's and St Thomas' NHS Foundation Trust, London, UK., Zisengwe G; King's College London, London, UK & Guy's and St Thomas' NHS Foundation Trust, London, UK., Elhage O; King's College London, London, UK & Guy's and St Thomas' NHS Foundation Trust, London, UK., Santaolalla A; King's College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology & Urology Research (TOUR), London, UK. aida.santaolalla@kcl.ac.uk.
Publikováno v:
BMC cancer [BMC Cancer] 2021 May 19; Vol. 21 (1), pp. 573. Date of Electronic Publication: 2021 May 19.
Autor:
van der Kwast TH; Department of Pathology, Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada. Electronic address: theodorus.vanderkwast@uhn.ca., Helleman J; Department of Urology, Erasmus MC, Rotterdam, The Netherlands., Nieboer D; Department of Urology, Erasmus MC, Rotterdam, The Netherlands; Department of Public Health, Erasmus MC, Rotterdam, The Netherlands., Bruinsma SM; Department of Urology, Erasmus MC, Rotterdam, The Netherlands., Roobol MJ; Department of Urology, Erasmus MC, Rotterdam, The Netherlands., Trock B; Johns Hopkins University, The James Buchanan Brady Urological Institute, Baltimore, MD, USA., Ehdaie B; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Carroll P; University of California San Francisco, San Francisco, CA, USA., Filson C; Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA., Kim J; MD Anderson Cancer Centre, Houston, TX, USA., Logothetis C; MD Anderson Cancer Centre, Houston, TX, USA., Morgan T; University of Michigan and Michigan Urological Surgery Improvement Collaborative, Michigan, USA., Klotz L; University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Pickles T; University of British Columbia, BC Cancer Agency, Vancouver, Canada., Hyndman E; University of Calgary, Southern Alberta Institute of Urology, Calgary, Canada., Moore CM; University College London and University College London Hospital Trust, London, UK., Gnanapragasam V; University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Van Hemelrijck M; King's College London, London, UK; Guy's and St Thomas' NHS Foundation Trust, London, UK., Dasgupta P; Guy's and St Thomas' NHS Foundation Trust, London, UK., Bangma C; Erasmus Medical Center, Rotterdam, The Netherlands., Roobol M; Erasmus Medical Center, Rotterdam, The Netherlands., Villers A; Lille University Hospital Center, Lille, France., Rannikko A; Helsinki University and Helsinki University Hospital, Helsinki, Finland., Valdagni R; Department of Oncology and Hemato-oncology, Università degli Studi di Milano, Radiation Oncology 1 and Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Perry A; University College Dublin, Dublin, Ireland., Hugosson J; Sahlgrenska University Hospital, Göteborg, Sweden., Rubio-Briones J; Instituto Valenciano de Oncología, Valencia, Spain., Bjartell A; Skåne University Hospital, Malmö, Sweden., Hefermehl L; Kan-tonsspital Baden, Baden, Switzerland., Shiong LL; Singapore General Hospital, Singapore, Singapore., Frydenberg M; Monash Health; Monash University, Melbourne, Australia., Kakehi Y; Kagawa University Faculty of Medicine, Kagawa, Japan., Chung BH; Gangnam Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea., van der Kwast T; Princess Margaret Cancer Centre, Toronto, Canada., Obbink H; Royal Philips, Eindhoven, The Netherlands., van der Linden W; Royal Philips, Eindhoven, The Netherlands., Hulsen T; Royal Philips, Eindhoven, The Netherlands., de Jonge C; Royal Philips, Eindhoven, The Netherlands., Kattan M; Cleveland Clinic, Cleveland, OH, USA., Xinge J; Cleveland Clinic, Cleveland, OH, USA., Muir K; University of Manchester, Manchester, UK., Lophatananon A; University of Manchester, Manchester, UK., Fahey M; Epworth HealthCare, Melbourne, Australia., Steyerberg E; Erasmus Medical Center, Rotterdam, The Netherlands., Nieboer D; Erasmus Medical Center, Rotterdam, The Netherlands., Zhang L; University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Guo W; Johns Hopkins University, The James Buchanan Brady Urological Institute, Baltimore, MD, USA., Benfante N; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Cowan J; University of California San Francisco, San Francisco, CA, USA., Patil D; Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA., Tolosa E; MD Anderson Cancer Centre, Houston, TX, USA., Kim TK; University of Michigan and Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI, USA., Mamedov A; University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., LaPointe V; University of British Columbia, BC Cancer Agency, Vancouver, Canada., Crump T; University of Calgary, Southern Alberta Institute of Urology, Calgary, Canada., Kimberly-Duffell J; University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Santaolalla A; King's College London, London, UK., Nieboer D; Erasmus Medical Center, Rotterdam, The Netherlands., Olivier JT; Lille University Hospital Center, Lille, France., Rancati T; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Ahlgren H; Sahlgrenska University Hospital, Göteborg, Sweden., Mascarós J; Instituto Valenciano de Oncología, Valencia, Spain., Löfgren A; Skåne University Hospital, Malmö, Sweden., Lehmann K; Kantonsspital Baden, Baden, Switzerland., Lin CH; Monash University and Epworth HealthCare, Melbourne, Australia., Hirama H; Kagawa University, Kagawa, Japan., Lee KS; Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea., Jenster G; Erasmus MC, Rotterdam, The Netherlands., Auvinen A; University of Tampere, Tampere, Finland., Bjartell A; Instituto Valenciano de Oncología, Valencia, Spain., Haider M; University of Toronto, Toronto, Canada., van Bochove K; The Hyve B.V. Utrecht, Utrecht, The Netherlands., Carter B; Johns Hopkins University, Baltimore, MD, USA., Gledhill S; Movember Foundation, Melbourne, Australia., Buzza M; Movember Foundation, Melbourne, Australia., Bangma C; Erasmus Medical Center, Rotterdam, The Netherlands., Roobol M; Erasmus Medical Center, Rotterdam, The Netherlands., Bruinsma S; Erasmus Medical Center, Rotterdam, The Netherlands., Helleman J; Erasmus Medical Center, Rotterdam, The Netherlands.
Publikováno v:
European urology oncology [Eur Urol Oncol] 2019 May; Vol. 2 (3), pp. 333-336. Date of Electronic Publication: 2018 Sep 13.
Autor:
Beckmann, Kerri, Santaolalla, Aida, Sugimoto, Mikio, Carroll, Peter, Rubio, Jose, Villers, Arnauld, Bjartell, Anders, Morgan, Todd, Dasgupta, Prokar, Van Hemelrijck, Mieke, Elhage, Oussama, Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium
Publikováno v:
Prostate cancer and prostatic diseases, vol 26, iss 2
BackgroundCurrently, follow-up protocols are applied equally to men on active surveillance (AS) for prostate cancer (PCa) regardless of findings at their initial follow-up biopsy. To determine whether less intensive follow-up is suitable following ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::9c99680c86f1ed8249c4298ddae8a8e3
https://escholarship.org/uc/item/5dk12186
https://escholarship.org/uc/item/5dk12186
Autor:
Bruinsma, Sophie M., Zhang, Liying, Roobol, Monique J., Bangma, Chris H., Steyerberg, Ewout W., Nieboer, Daan, Van Hemelrijck, Mieke, Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Kim, Jeri, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline M., Gnanapragasam, Vincent, Dasgupta, Prokar, Villers, Arnauld, Rannikko, Antti, Valdagni, Riccardo, Perry, Antoinette, Hugosson, Jonas, Rubio-Briones, Jose, Bjartell, Anders, Hefermehl, Lukas, Lui Shiong, Lee, Frydenberg, Mark, Kakehi, Yoshiyuki, Ha Chung, Byung, van der Kwast, Theo, Obbink, Henk, van der Linden, Wim, Hulsen, Tim, de Jonge, Cees, Kattan, Mike, Xinge, Ji, Muir, Kenneth, Lophatananon, Artitaya, Fahey, Michael, Guo, Wei, Milan, Tanya, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Sanford, Rachel, Kim, Tae Kyung, Mamedov, Alexandre, Santaolalla, Aida
Publikováno v:
BJU International, 121(5), 737-744. Wiley-Blackwell Publishing Ltd
Bruinsma, S M, Zhang, L, Roobol, M J, Bangma, C H, Steyerberg, E W, Nieboer, D, Van Hemelrijck, M, Trock, B, Ehdaie, B, Carroll, P, Filson, C, Kim, J, Morgan, T, Klotz, L, Pickles, T, Hyndman, E, Moore, C M, Gnanapragasam, V, Dasgupta, P, Villers, A, Rannikko, A, Valdagni, R, Perry, A, Hugosson, J, Rubio-Briones, J, Bjartell, A, Hefermehl, L, Lui Shiong, L, Frydenberg, M, Kakehi, Y, Ha Chung, B, van der Kwast, T, Obbink, H, van der Linden, W, Hulsen, T, de Jonge, C, Kattan, M, Xinge, J, Muir, K, Lophatananon, A, Fahey, M, Guo, W, Milan, T, Benfante, N, Cowan, J, Patil, D, Sanford, R, Kim, T K & Mamedov, A & Santaolalla, A 2018, ' The Movember Foundation's GAP3 cohort : a profile of the largest global prostate cancer active surveillance database to date ', BJU International, vol. 121, no. 5, pp. 737-744 . https://doi.org/10.1111/bju.14106
Bruinsma, S M, Zhang, L, Roobol, M J, Bangma, C H, Steyerberg, E W, Nieboer, D, Van Hemelrijck, M, Trock, B, Ehdaie, B, Carroll, P, Filson, C, Kim, J, Morgan, T, Klotz, L, Pickles, T, Hyndman, E, Moore, C M, Gnanapragasam, V, Dasgupta, P, Villers, A, Rannikko, A, Valdagni, R, Perry, A, Hugosson, J, Rubio-Briones, J, Bjartell, A, Hefermehl, L, Lui Shiong, L, Frydenberg, M, Kakehi, Y, Ha Chung, B, van der Kwast, T, Obbink, H, van der Linden, W, Hulsen, T, de Jonge, C, Kattan, M, Xinge, J, Muir, K, Lophatananon, A, Fahey, M, Guo, W, Milan, T, Benfante, N, Cowan, J, Patil, D, Sanford, R, Kim, T K & Mamedov, A & Santaolalla, A 2018, ' The Movember Foundation's GAP3 cohort : a profile of the largest global prostate cancer active surveillance database to date ', BJU International, vol. 121, no. 5, pp. 737-744 . https://doi.org/10.1111/bju.14106
Objectives: The Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative to create a global consensus on the selection and monitoring of men with low-risk prostate cancer (PCa) on active surveillance (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0125e3b21d61bac090b1a64824d825b
https://pure.eur.nl/en/publications/a5a1ac36-c3a7-4c25-92cf-ce035e3f0856
https://pure.eur.nl/en/publications/a5a1ac36-c3a7-4c25-92cf-ce035e3f0856
Autor:
Shah, Salonee, Beckmann, Kerri, Van Hemelrijck, Mieke, Challacombe, Ben, Popert, Rick, Dasgupta, Prokar, Rusere, Jonah, Zisengwe, Grace, Elhage, Oussama, Santaolalla, Aida
Publikováno v:
BMC Cancer; 1/24/2022, Vol. 22 Issue 1, p1-1, 1p
Autor:
Kerri R, Beckmann, Chris H, Bangma, Jozien, Helleman, Anders, Bjartell, Peter R, Carroll, Todd, Morgan, Daan, Nieboer, Aida, Santaolalla, Bruce J, Trock, Riccardo, Valdagni, Monique J, Roobol
Publikováno v:
Prostate, 82(7), 876-879. Wiley-Liss Inc.
2022, ' Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer : An analysis of the G.A.P.3 global consortium database ', Prostate, vol. 82, no. 7, pp. 876-879 . https://doi.org/10.1002/pros.24330
2022, ' Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer : An analysis of the G.A.P.3 global consortium database ', Prostate, vol. 82, no. 7, pp. 876-879 . https://doi.org/10.1002/pros.24330
Refereed/Peer-reviewed Background: The optimal interval for repeat biopsy during active surveillance (AS) for prostate cancer is yet to be defined. This study examined whether risk of upgrading (to grade group ≥ 2) or risk of converting to treatmen
Autor:
Kerri Beckmann, Benjamin Challacombe, Sharon Clovis, Oussama Elhage, Christian Brown, Prokar Dasgupta, Aida Santaolalla, Rick Popert, Preeti Sandhu, Paul Cathcart, Mieke Van Hemelrijck, Sohail Singh, Grace Zisengwe, Kamal Dewan, Jonah Rusere
To determine the risk of disease progression and conversion to active treatment following a negative biopsy while on active surveillance (AS) for prostate cancer (PCa).Men on an AS programme at a single tertiary hospital (London, UK) between 2003 and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6eb7104cd7401c6841dc2ed705b22fb5
https://hdl.handle.net/11541.2/144947
https://hdl.handle.net/11541.2/144947